Evolving Considerations in the Treatment and Management of Hereditary Angioedema (HAE): Managed Care Strategies in an Evolving Treatment Paradigm

A continuing medical education activity provided by NAMCP and AAMCN

This activity is an archive of the live session from the 2021 Spring Managed Care Forum.
If you participated in the live session, you are not eligible for
continuing education credits from this archive.

This activity is valid from May 1, 2021 – August 1, 2022
 

Instructions for CME/NCPD: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.

 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This activity is supported by an educational grant from
CSL Behring

Description:
Hereditary angioedema (HAE) is a rare autosomal dominant condition characterized by recurrent attacks of edema at different locations of the body. This potentially life-threatening disease affects approximately 1 in 67,000 individuals, with no identified differences in sex or ethnicity. HAE is characterized by recurrent edema attacks and the cutaneous attacks can be disabling, with the skin, gastrointestinal tract, and upper airways are most commonly affected and with a persistent risk to the patient of acute events of laryngeal swelling that may prove fatal if not treated in a timely manner. Angioedema in general can be confused with cellulitis, Graves disease, blepharochalasis, eosinophilic fasciitis, or amyloidosis which can lead to delays in diagnosis, and inappropriate treatment poses the risk of adverse events, unnecessary surgical interventions, a higher burden of misery, and a potentially higher rate of morbidity and mortality. Fortunately for patients with HAE, novel therapies have recently become available in the past year and a half that have shown improved efficacy and safety with improved administration methods. With these new options comes a knowledge gap among physician medical directors, pharmacists, immunologists and nurse case managers as the treatment paradigm is growing. For this reason, it is critical that these HCPs are educated and updated on these emerging options and strategies for their implementation into the treatment paradigm, including throughout formulary and health plan discussions, which will ultimately improve patient outcomes in the HAE patient population.

Early diagnosis and treatment of HAE is extremely important for all patients affected by this disorder. An individualized treatment plan should be developed in close collaboration with their clinicians in order to improve the quality of life of patients with HAE. The burden of this disease is increased with delayed diagnosis, inappropriate treatment, and limited patient access. Delays in diagnosis remain, as healthcare professionals often fail to include HAE in the differential diagnosis when patients present with attacks. Patients are therefore often misdiagnosed for several years before a diagnosis of HAE is finally made. Early diagnosis of the disease can lead to the development of an individualized treatment plan that assists in the prevention and management of attacks. Managed care clinicians and providers must be educated surrounding recognition of HAE and early diagnosis, prompt intervention for both acute treatment needs and long-term prevention, and HAE best practices, including newer and emerging agents for treatment of the disease. With this education, they can reduce symptom severity and occurrence, and improve outcomes in patients with this rare but serious disorder.

Upon completion of this activity, participants will be able to:

  • Describe the pathophysiology, etiology and challenges preventing the early diagnosis of hereditary angioedema (HAE)

  • Discuss ways to identify patients with HAE earlier by utilizing appropriate testing consistently for optimal diagnosis

  • Analyze safety and efficacy data of recently approved therapies for the prophylaxis of HAE

  • Explore the evolving role of C1-INH replacement therapy in the management of HAE

  • Assess novel administration methods for novel therapies and how they are changing the treatment paradigm

  • Apply methods to enable optimal cost management of novel therapies to be realized by multiple HAE stakeholders including managed care organizations

     

Faculty: Marc Riedl, MD, MS
Professor of Medicine
Clinical Director – US HAEA Angioedema Center
Clinical Service Chief & Training Program Director
Division of Rheumatology, Allergy & Immunology
University of California, San Diego

Disclosure:

Dr. Riedl serves as a consultant for Biocryst, CSL Behring, Ionis, Takeda, Adverum, Pharming, Attune, Biomarin, Pharvaris, Regenxbio, Kalvista, and Pfizer. He has received grants/research funding from Biocryst, CSL Behring, Ionis, and Takeda. He has served on the speaker's bureau for CSL Behring, Takeda, Pharming, and Grifols. His presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no financial relationships with ineligible companies to disclose.
Jeremy Williams has no financial relationships with ineligible companies to disclose.
Jacqueline Cole, RN, MS, CMCN has no financial relationships with ineligible companies to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association of Managed Care Physicians (NAMCP) and American Association of Managed Care Nurses (AAMCN). The National Association of Managed Care Physicians is accredited by the ACCME to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in nursing continuing professional development.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This activity is supported by an educational grant from
CSL Behring

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue